UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on DexCom
In a report published Friday, Jefferies & Company reiterated its Buy rating on DexCom (NASDAQ: DXCM), but lowered its price target from $18.00 to $16.50.
Jefferies noted, “DexCom released final 3Q revenues of $23.1mn after pre-announcing in early October with the G4 Platinum Sensor approval. The final 3Q numbers reflect a handful of one-time charges and adjustments; full year guidance was reiterated. The G4 and the subsequent pump combinations set the table for a good run.”
DexCom closed on Thursday at $13.07.
Latest Ratings for DXCM
|Dec 2014||JP Morgan||Maintains||Overweight|
|Dec 2014||Cowen & Company||Initiates Coverage on||Outperform|
|Nov 2014||JP Morgan||Maintains||Overweight|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.